Spruce biosciences reports first quarter 2024 financial results and provides corporate updates

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended march 31, 2024 and provided corporate updates. “we are encouraged by key learnings from analyses of data from our cahmelia-203 clinical trial in adult cah patients with severe hyperandroge.
SPRB Ratings Summary
SPRB Quant Ranking